|
Market Closed -
Nasdaq
16:00:00 2026-09-17 EDT
|
5-day change | 1st Jan Change | ||
| 5.170 USD | +2.38% |
|
-6.00% | -44.53% |
Company Valuation: Aligos Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 505.9 | 40.8 | 49.75 | 147.9 | 57.35 | 31.54 | - | - |
| Change | - | -91.93% | 21.95% | 197.2% | -61.21% | -45.01% | - | - |
| Enterprise Value (EV) 1 | 505.9 | 40.8 | 49.75 | 147.9 | -20.46 | -2.071 | -266.6 | -164.6 |
| Change | - | -91.93% | 21.95% | 197.2% | -113.83% | 89.88% | -12,775.22% | 38.26% |
| P/E | -3.69x | -0.42x | -0.49x | -1.9x | -3.8x | -0.78x | -0.94x | -1.93x |
| PBR | 2.74x | - | - | - | 1.72x | 13.8x | 0.58x | 0.95x |
| PEG | - | 0x | 0x | 0x | 0x | -0x | 0.1x | 0x |
| Capitalization / Revenue | 116x | 2.93x | 5.33x | 37.5x | 26.2x | 0.88x | 6.78x | 0.61x |
| EV / Revenue | 116x | 2.93x | 5.33x | 37.5x | -9.36x | -0.06x | -57.3x | -3.16x |
| EV / EBITDA | -3.94x | - | - | - | 0.23x | 0.02x | 2.23x | 1.29x |
| EV / EBIT | -3.94x | -0.42x | -0.56x | -1.66x | 0.23x | 0.02x | 2.09x | 1.58x |
| EV / FCF | -4.34x | - | - | - | 0.25x | 0.02x | 2.23x | 1.2x |
| FCF Yield | -23% | - | - | - | 405% | 4,075% | 44.9% | 83.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -80.5 | -56.25 | -34 | -20.94 | -2.45 | -6.478 | -5.374 | -2.614 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.359 | 13.91 | 9.338 | 3.945 | 2.186 | 35.99 | 4.65 | 52.08 |
| EBITDA 1 | -128.3 | - | - | - | -87.06 | -93.01 | -119.4 | -127.9 |
| EBIT 1 | -128.3 | -97.58 | -88.13 | -89.15 | -87.98 | -84.93 | -127.7 | -103.9 |
| Net income 1 | -128.3 | -96.05 | -87.68 | -131.2 | -24.19 | -79.34 | -124.9 | -101 |
| Net Debt 1 | - | - | - | - | -77.81 | -33.61 | -298.2 | -196.2 |
| Reference price 2 | 296.750 | 23.822 | 16.600 | 39.840 | 9.320 | 5.050 | 5.050 | 5.050 |
| Nbr of stocks (in thousands) | 1,705 | 1,713 | 2,997 | 3,712 | 6,154 | 6,245 | - | - |
| Announcement Date | 3/10/22 | 3/9/23 | 3/12/24 | 3/10/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.78x | -0.06x | 0.02x | -.--% | 31.54M | |
| 31.46x | 5.67x | 16.98x | 1.03% | 45.91B | |
| 34.62x | 3.34x | 14.39x | -.--% | 44.25B | |
| -20.04x | 230.9x | -21.44x | -.--% | 41.99B | |
| 45.6x | 5.26x | 28.79x | -.--% | 39.58B | |
| 26.88x | 8.11x | 20.55x | 0.42% | 31.08B | |
| 35.05x | 5.75x | 26.13x | -.--% | 17.21B | |
| 24.9x | 2.15x | 9.33x | 1.07% | 14.96B | |
| 29.53x | 1.94x | 11.89x | -.--% | 13.42B | |
| Average | 23.02x | 29.23x | 11.85x | 0.28% | 27.6B | |
| Weighted average by Cap. | 24.74x | 43.16x | 12.25x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALGS Stock
- Valuation Aligos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
